We mark this as pharmacogenetic because it is normally benign, but could be pathogenic in the context of medical treatment — i.e. it might affect the type of medical treatment an individual would receive.
Assuming a GVHD rate of 30% in HLA matched siblings, the mismatched PECAM genotypes have a risk of ~58%, an attributable increased risk of ~28%.